Literature DB >> 8757876

Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.

T R Kozel1, L C Weinhold, D M Lupan.   

Abstract

Candida albicans is a potent activator of the complement system. The objective of this study was to characterize factors that influence the kinetics for activation of C3 and binding of C3 fragments to C. albicans. Factors that were examined included the surface properties of the yeast and contributions of the classical and alternative complement pathways. The results showed that incubation of hydrophobic, hydrophilic, or germinating yeast cells in normal human serum (NHS) containing radiolabeled C3 led to immediate accumulation of C3 on all three cell types, although the rate of accumulation of C3 on germinating cells was lower. An examination of the sites for early C3 binding showed that classical pathway initiation led to immediate, synchronous binding over the entire cell surface. A blockade of the classical pathway by absorption of putative classical pathway initiators or by chelation of calcium limited activation to the alternative pathway. Binding of C3 solely via the alternative pathway was characterized by a significant lag in the initial binding kinetics. In the absence of classical pathway initiation, the early cellular sites for C3 binding appeared as random, asynchronous foci of C3 that appeared to expand with time. The factor(s) mediating rapid deposition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-absorbed by hydrophilic and hydrophobic C. albicans but was not removed by absorption of NHS with Saccharomyces cerevisiae, encapsulated Cryptococcus neoformans, or nonencapsulated C. neoformans. Delayed binding of C3 produced by absorption of serum was largely reversed by addition to the absorbed serum of immunoglobulin G isolated from NHS, indicating a significant role for a naturally occurring anti-C. albicans immunoglobulin C. in classical pathway initiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757876      PMCID: PMC174230          DOI: 10.1128/iai.64.8.3360-3368.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Dynamic changes of the cell wall surface of Candida albicans associated with germination and adherence.

Authors:  G Tronchin; J P Bouchara; R Robert
Journal:  Eur J Cell Biol       Date:  1989-12       Impact factor: 4.492

3.  Alternative pathway of complement activation by Candida albicans.

Authors:  Y H Thong; A Ferrante
Journal:  Aust N Z J Med       Date:  1978-12

4.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; W H Welch
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

6.  Differential adherence of hydrophobic and hydrophilic Candida albicans yeast cells to mouse tissues.

Authors:  K C Hazen; D L Brawner; M H Riesselman; M A Jutila; J E Cutler
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b.

Authors:  F Heidenreich; M P Dierich
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Role of complement during experimental Candida infection in mice.

Authors:  R Morelli; L T Rosenberg
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441

9.  Antibody response that protects against disseminated candidiasis.

Authors:  Y Han; J E Cutler
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients.

Authors:  P F Lehmann; E Reiss
Journal:  Mycopathologia       Date:  1980-03-17       Impact factor: 2.574

View more
  21 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.

Authors:  Mason X Zhang; M Charlotte Bohlman; Carol Itatani; Dennis R Burton; Paul W H I Parren; Stephen C St Jeor; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 4.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

5.  Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.

Authors:  Gayle M Boxx; Thomas R Kozel; Casey T Nishiya; Mason X Zhang
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

6.  The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein.

Authors:  T Meri; A M Blom; A Hartmann; D Lenk; S Meri; P F Zipfel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.

Authors:  M X Zhang; J E Cutler; Y Han; T R Kozel
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Minimum chemical requirements for adhesin activity of the acid-stable part of Candida albicans cell wall phosphomannoprotein complex.

Authors:  T Kanbe; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Authors:  Gayle M Boxx; Casey T Nishiya; Thomas R Kozel; Mason X Zhang
Journal:  Mol Immunol       Date:  2008-11-26       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.